34 results
8-K
EX-99.2
LUMO
Lumos Pharma Inc
21 Jun 23
Lumos to Highlight New LUM-201 Data and Analysis Presented
5:10pm
and gender Slight imbalance in delta below MPH, BMI, and bone age delay KEY: SDS = Standard deviation score MPH = Mid-parental height (Child’s target
8-K
EX-99.2
LUMO
Lumos Pharma Inc
12 Dec 22
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
5:20pm
for 3.2 mg subjects 24 Patient Gender Age (months) Dose (mg/kg) Height (SDS) Clonidine test (GH ng/mL) PEM test (GH ng/mL) time 0 peak peak 801-101 F
8-K/A
5n3p5 wlj
1 Jun 20
Other Events
12:00am
8-K
EX-10.2
d92a3pbrtbv6qtt
18 Mar 20
NewLink Genetics Stockholders Approve Merger with Lumos Pharma
4:37pm
DEFR14A
fpgnm ktax0lcv1hf
13 Feb 20
Revised proxy
4:37pm
DEFM14A
2khpm
10 Feb 20
Proxy related to merger
8:30am
PRER14A
rnt67jcdjd
9 Jan 20
Preliminary revised proxy
8:02am
PREM14A
vvgys
20 Nov 19
Preliminary proxy related to merger
6:38am
8-K
EX-2.1
81onuom
30 Sep 19
Entry into a Material Definitive Agreement
12:00am
DEFA14A
EX-2.2
chfajpi2k y4j
30 Sep 19
Additional proxy soliciting materials
12:00am
8-K
EX-2.2
99myyqka72ouk0u qg
30 Sep 19
Entry into a Material Definitive Agreement
12:00am
DEFA14A
EX-2.1
8s3vyq16vo 6k9r7j
30 Sep 19
Additional proxy soliciting materials
12:00am